{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:12:31Z","timestamp":1790799151040,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18H06332"],"award-info":[{"award-number":["18H06332"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["18K09866, 16K20655"],"award-info":[{"award-number":["18K09866, 16K20655"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K11993"],"award-info":[{"award-number":["17K11993"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["16H01635, 18H04986, 16K15778"],"award-info":[{"award-number":["16H01635, 18H04986, 16K15778"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25293066, 15K15538"],"award-info":[{"award-number":["25293066, 15K15538"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24659830, 26293398"],"award-info":[{"award-number":["24659830, 26293398"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["S1411009, S1201014, S0801016"],"award-info":[{"award-number":["S1411009, S1201014, S0801016"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The anti-bone resorptive drugs denosumab, an anti-human-RANKL antibody, and zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, have recently been applied for treatment of pediatric patients with bone diseases, though details regarding their effects in growing children have yet to be fully elucidated. In the present study, we administered these anti-resorptive drugs to mice from the age of 1 week and continued once-weekly injections for a total of 7 times. Mice that received the anti-RANKL antibody displayed normal growth and tooth eruption, though osteopetrotic bone volume gain in long and alveolar bones was noted, while there were nearly no osteoclasts and a normal of number osteoblasts observed. In contrast, ZOL significantly delayed body growth, tooth root formation, and tooth eruption, with increased osteoclast and decreased osteoblast numbers. These findings suggest regulation of tooth eruption via osteoblast differentiation by some types of anti-resorptive drugs.<\/jats:p>","DOI":"10.1038\/s41598-019-56151-1","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T06:03:12Z","timestamp":1577426592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice"],"prefix":"10.1038","volume":"9","author":[{"given":"Motoki","family":"Isawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2099-7293","authenticated-orcid":false,"given":"Akiko","family":"Karakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0240-6480","authenticated-orcid":false,"given":"Nobuhiro","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saki","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miku","family":"Kuritani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Chatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7780-140X","authenticated-orcid":false,"given":"Takako","family":"Negishi-Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-3975","authenticated-orcid":false,"given":"Masamichi","family":"Takami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,27]]},"reference":[{"key":"56151_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.abb.2014.07.034","volume":"561","author":"KBS Paiva","year":"2014","unstructured":"Paiva, K. B. S. & Granjeiro, J. M. Bone tissue remodeling and development: focus on matrix metalloproteinase functions. Arch. Biochem. Biophys. 561, 74\u201387 (2014).","journal-title":"Arch. Biochem. Biophys."},{"key":"56151_CR2","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504\u20131508 (2000).","journal-title":"Science"},{"key":"56151_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher, K. N., Guise, T. A. & McCauley, L. K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 11, 411\u201325 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"56151_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1006\/bbrc.1999.0252","volume":"256","author":"N Takahashi","year":"1999","unstructured":"Takahashi, N., Udagawa, N. & Suda, T. A new member of tumor necrosis factor ligand family, ODF\/OPGL\/TRANCE\/RANKL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256, 449\u2013455 (1999).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"56151_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S8756-3282(99)00214-8","volume":"25","author":"V Kartsogiannis","year":"1999","unstructured":"Kartsogiannis, V. et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 25, 525\u201334 (1999).","journal-title":"Bone"},{"key":"56151_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1210\/er.2007-0014","volume":"29","author":"AE Kearns","year":"2008","unstructured":"Kearns, A. E., Khosla, S. & Kostenuik, P. J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 29, 155\u2013192 (2008).","journal-title":"Endocr. Rev."},{"key":"56151_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas, G. H. et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38, 617\u201327 (2006).","journal-title":"Bone"},{"key":"56151_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1359\/jbmr.2000.15.8.1467","volume":"15","author":"FP Coxon","year":"2000","unstructured":"Coxon, F. P. et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J. Bone Miner. Res. 15, 1467\u20131476 (2000).","journal-title":"J. Bone Miner. Res."},{"key":"56151_CR9","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125\u20131132 (2011).","journal-title":"J. Clin. Oncol."},{"key":"56151_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/MOU.0b013e3283449e19","volume":"21","author":"G Sonpavde","year":"2011","unstructured":"Sonpavde, G. & Sternberg, C. N. Contemporary management of metastatic castration-resistant prostate cancer. Curr. Opin. Urol. 21, 241\u2013247 (2011).","journal-title":"Curr. Opin. Urol."},{"key":"56151_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.4158\/EP14106.OR","volume":"21","author":"K Sheedy","year":"2015","unstructured":"Sheedy, K., Camara, M. & Camacho, P. Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis. Endocr. Pract. 21, 275\u2013279 (2015).","journal-title":"Endocr. Pract."},{"key":"56151_CR12","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000323368","volume":"75","author":"I Vuorimies","year":"2011","unstructured":"Vuorimies, I., Toiviainen-Salo, S., Hero, M. & M\u00e4kitie, O. Zoledronic acid treatment in children with osteogenesis imperfecta. Horm. Res. Paediatr. 75, 346\u2013353 (2011).","journal-title":"Horm. Res. Paediatr."},{"key":"56151_CR13","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn, H. et al. Safety and efficacy of denosumab in children with osteogenesis imperfect\u2013a first prospective trial. J. Musculoskelet. Neuronal Interact. 16, 24\u201332 (2016).","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"56151_CR14","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1200\/JCO.2012.46.4255","volume":"31","author":"NA Karras","year":"2013","unstructured":"Karras, N. A. et al. Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J. Clin. Oncol. 31, e200\u2013e202 (2013).","journal-title":"J. Clin. Oncol."},{"key":"56151_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2013.10.004","volume":"58","author":"F Cornelis","year":"2014","unstructured":"Cornelis, F. et al. Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy. Bone 58, 11\u201316 (2014).","journal-title":"Bone"},{"key":"56151_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1210\/jc.2008-1531","volume":"94","author":"LK Bachrach","year":"2009","unstructured":"Bachrach, L. K. & Ward, L. M. Clinical review: Bisphosphonate use in childhood osteoporosis. J. Clin. Endocrinol. Metab. 94, 400\u2013409 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"56151_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000354303","volume":"80","author":"HL Ooi","year":"2013","unstructured":"Ooi, H. L., Briody, J., Biggin, A., Cowell, C. T. & Munns, C. F. Intravenous zoledronic acid given every 6 months in childhood osteoporosis. Horm. Res. Paediatr. 80, 179\u2013184 (2013).","journal-title":"Horm. Res. Paediatr."},{"key":"56151_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/pbc.22681","volume":"56","author":"KJ August","year":"2011","unstructured":"August, K. J. et al. The use of zoledronic acid in pediatric cancer patients. Pediatr. Blood Cancer 56, 610\u2013614 (2011).","journal-title":"Pediatr. Blood Cancer"},{"key":"56151_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nrendo.2009.58","volume":"5","author":"JC Marini","year":"2009","unstructured":"Marini, J. C. Use of bisphosphonates in children\u2014proceed with caution. Nat. Rev. Endocrinol. 5, 241\u2013243 (2009).","journal-title":"Nat. Rev. Endocrinol."},{"key":"56151_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","volume":"34","author":"N Setsu","year":"2016","unstructured":"Setsu, N. et al. Severe hypercalcemia following denosumab treatment in a juvenile patient. J. Bone Miner. Metab. 34, 118\u2013122 (2016).","journal-title":"J. Bone Miner. Metab."},{"key":"56151_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrg1380","volume":"5","author":"A Tucker","year":"2004","unstructured":"Tucker, A. & Sharpe, P. The cutting-edge of mammalian development; how the embryo makes teeth. Nat. Rev. Genet. 5, 499\u2013508 (2004).","journal-title":"Nat. Rev. Genet."},{"key":"56151_CR22","doi-asserted-by":"publisher","first-page":"e12740","DOI":"10.1111\/ecc.12740","volume":"26","author":"P Katsimbri","year":"2017","unstructured":"Katsimbri, P. The biology of normal bone remodelling. Eur. J. Cancer Care (Engl). 26, e12740 (2017).","journal-title":"Eur. J. Cancer Care (Engl)."},{"key":"56151_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315\u2013323 (1999).","journal-title":"Nature"},{"key":"56151_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bone.2014.08.018","volume":"68","author":"F L\u00e9zot","year":"2014","unstructured":"L\u00e9zot, F. et al. Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies. Bone 68, 146\u2013152 (2014).","journal-title":"Bone"},{"key":"56151_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bone.2014.12.011","volume":"73","author":"F L\u00e9zot","year":"2015","unstructured":"L\u00e9zot, F. et al. Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: mouse strain disparities and synergic effect with zoledronic acid. Bone 73, 51\u201359 (2015).","journal-title":"Bone"},{"key":"56151_CR26","doi-asserted-by":"publisher","first-page":"37023","DOI":"10.1074\/jbc.M111.246280","volume":"286","author":"Y Furuya","year":"2011","unstructured":"Furuya, Y. et al. Increased bone mass in mice after single injection of anti-receptor activator of nuclear factor-kappaB ligand-neutralizing antibody: evidence for bone anabolic effect of parathyroid hormone in mice with few osteoclasts. J. Biol. Chem. 286, 37023\u201337031 (2011).","journal-title":"J. Biol. Chem."},{"key":"56151_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1053\/j.ajkd.2006.11.045","volume":"49","author":"A Yajima","year":"2007","unstructured":"Yajima, A., Inaba, M., Tominaga, Y. & Ito, A. Minimodeling reduces the rate of cortical bone loss in patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 49, 440\u2013451 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"56151_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10520298909106985","volume":"64","author":"AR Villanueva","year":"1989","unstructured":"Villanueva, A. R. & Lundin, K. D. A versatile new mineralized bone stain for simultaneous assessment of tetracycline and osteoid seams. Stain Technol. 64, 129\u2013138 (1989).","journal-title":"Stain Technol."},{"key":"56151_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40272-013-0051-3","volume":"16","author":"N Federman","year":"2014","unstructured":"Federman, N. et al. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets. Pediatr. Drugs 16, 21\u201328 (2014).","journal-title":"Pediatr. Drugs"},{"key":"56151_CR30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(16)30096-1","volume":"17","author":"S Piperno-Neumann","year":"2016","unstructured":"Piperno-Neumann, S. et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 17, 1070\u20131080 (2016).","journal-title":"Lancet Oncol."},{"key":"56151_CR31","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972\u2013980 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"56151_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00774-016-0806-3","volume":"35","author":"M Shiraki","year":"2017","unstructured":"Shiraki, M., Tanaka, S., Suzuki, H., Ueda, S. & Nakamura, T. Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. J. Bone Miner. Metab. 35, 675\u2013684 (2017).","journal-title":"J. Bone Miner. Metab."},{"key":"56151_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.bone.2003.08.013","volume":"34","author":"B Pan","year":"2004","unstructured":"Pan, B. et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro. Bone 34, 112\u2013123 (2004).","journal-title":"Bone"},{"key":"56151_CR34","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/jbmr.453","volume":"26","author":"S Battaglia","year":"2011","unstructured":"Battaglia, S. et al. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: Preclinical studies and case report of an osteosarcoma pediatric patient. J. Bone Miner. Res. 26, 2439\u20132451 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"56151_CR35","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1021\/tx700151t","volume":"20","author":"F Dieterle","year":"2007","unstructured":"Dieterle, F. et al. Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates. Chem. Res. Toxicol. 20, 1291\u20131299 (2007).","journal-title":"Chem. Res. Toxicol."},{"key":"56151_CR36","first-page":"115","volume":"12","author":"Y Lu","year":"2013","unstructured":"Lu, Y. et al. Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis. EXCLI J. 12, 115\u2013117 (2013).","journal-title":"EXCLI J."},{"key":"56151_CR37","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.4049\/jimmunol.179.11.7497","volume":"179","author":"M Stolina","year":"2007","unstructured":"Stolina, M. et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J. Immunol. 179, 7497\u20137505 (2007).","journal-title":"J. Immunol."},{"key":"56151_CR38","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","volume":"49","author":"MJ Rogers","year":"2011","unstructured":"Rogers, M. J., Crockett, J. C., Coxon, F. P. & M\u00f6nkk\u00f6nen, J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49, 34\u201341 (2011).","journal-title":"Bone"},{"key":"56151_CR39","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/odi.12587","volume":"23","author":"J Vermeer","year":"2017","unstructured":"Vermeer, J. et al. Bone-site-specific responses to zoledronic acid. Oral Dis. 23, 126\u2013133 (2017).","journal-title":"Oral Dis."},{"key":"56151_CR40","first-page":"1","volume":"12","author":"Z Stark","year":"2009","unstructured":"Stark, Z. & Savarirayan, R. Review Osteopetrosis. Orphanet J. Rare Dis. 12, 1\u201312 (2009).","journal-title":"Orphanet J. Rare Dis."},{"key":"56151_CR41","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1359\/JBMR.050604","volume":"20","author":"EJ Smith","year":"2005","unstructured":"Smith, E. J. et al. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits. J. Bone Miner. Res. 20, 1731\u20131741 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"56151_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0003-9969(84)90105-5","volume":"29","author":"SC Marks","year":"1984","unstructured":"Marks, S. C. & Cahill, D. R. Experimental study in the dog of the non-active role of the tooth in the eruptive process. Arch. Oral Biol. 29, 311\u2013322 (1984).","journal-title":"Arch. Oral Biol."},{"key":"56151_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1600-0714.1985.tb00461.x","volume":"14","author":"GE Wise","year":"1985","unstructured":"Wise, G. E., Marks, S. C. & Cahill, D. R. Ultrastructural features of the dental follicle associated with formation of the tooth eruption pathway in the dog. J. Oral Pathol. 14, 15\u201326 (1985).","journal-title":"J. Oral Pathol."},{"key":"56151_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00774-003-0481-z","volume":"22","author":"T Suzuki","year":"2004","unstructured":"Suzuki, T., Suda, N. & Ohyama, K. Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NF kappa-B ligand (RANKL). J. Bone Miner. Metab. 22, 185\u2013191 (2004).","journal-title":"J. Bone Miner. Metab."},{"key":"56151_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1600-0722.2006.00406.x","volume":"114","author":"GE Wise","year":"2006","unstructured":"Wise, G. E. & Yao, S. Regional differences of expression of bone morphogenetic protein-2 and RANKL in the rat dental follicle. Eur. J. Oral Sci. 114, 512\u2013516 (2006).","journal-title":"Eur. J. Oral Sci."},{"key":"56151_CR46","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/154405910808700509","volume":"87","author":"GE Wise","year":"2008","unstructured":"Wise, G. E. & King, G. J. Mechanisms of tooth eruption and orthodontic tooth movement. J. Dent. Res. 87, 414\u2013434 (2008).","journal-title":"J. Dent. Res."},{"key":"56151_CR47","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1177\/00220345000790120301","volume":"79","author":"GE Wise","year":"2000","unstructured":"Wise, G. E., Lumpkin, S. J., Huang, H. & Zhang, Q. Osteoprotegerin and osteoclast differentiation factor in tooth eruption. J. Dent. Res. 79, 1937\u20131942 (2000).","journal-title":"J. Dent. Res."},{"key":"56151_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1600-0722.2008.00529.x","volume":"116","author":"A Kamoun-Goldrat","year":"2008","unstructured":"Kamoun-Goldrat, A., Ginisty, D. & Le Merrer, M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur. J. Oral Sci. 116, 195\u2013198 (2008).","journal-title":"Eur. J. Oral Sci."},{"key":"56151_CR49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/jop.12516","volume":"46","author":"M Hernandez","year":"2017","unstructured":"Hernandez, M., Phulpin, B., Mansuy, L. & Droz, D. Use of new targeted cancer therapies in children: effects on dental development and risk of jaw osteonecrosis: a review. J. Oral Pathol. Med. 46, 321\u2013326 (2017).","journal-title":"J. Oral Pathol. Med."},{"key":"56151_CR50","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1177\/00220345420210040901","volume":"21","author":"H Sicher","year":"1942","unstructured":"Sicher, H. Tooth eruption: axial movement of teeth with limited growth. J. Dent. Res. 21, 395\u2013402 (1942).","journal-title":"J. Dent. Res."},{"key":"56151_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1601-6343.2009.01439.x","volume":"12","author":"G Wise","year":"2009","unstructured":"Wise, G. Cellular and molecular basis of tooth eruption. Orthod. Craniofac. Res. 12, 67\u201373 (2009).","journal-title":"Orthod. Craniofac. Res."},{"key":"56151_CR52","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1073\/pnas.1810200115","volume":"116","author":"A Takahashi","year":"2019","unstructured":"Takahashi, A. et al. Autocrine regulation of mesenchymal progenitor cell fates orchestrates tooth eruption. Proc. Natl. Acad. Sci. USA 116, 575\u2013580 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"56151_CR53","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/j.1469-7580.2011.01367.x","volume":"218","author":"V Lungov\u00e1","year":"2011","unstructured":"Lungov\u00e1, V. et al. Tooth-bone morphogenesis during postnatal stages of mouse first molar development. J. Anat. 218, 699\u2013716 (2011).","journal-title":"J. Anat."},{"key":"56151_CR54","first-page":"927","volume":"75","author":"M Leonardi","year":"2005","unstructured":"Leonardi, M., Armi, P., Baccetti, T., Franchi, L. & Caltabiano, M. Mandibular growth in subjects with infraoccluded deciduous molars: A superimposition study. Angle Orthod. 75, 927\u2013934 (2005).","journal-title":"Angle Orthod."},{"key":"56151_CR55","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1172\/JCI42528","volume":"120","author":"K Nishikawa","year":"2010","unstructured":"Nishikawa, K. et al. Maf promotes osteoblast differentiation in mice by mediating the age-related switch in mesenchymal cell differentiation. J. Clin. Invest. 120, 3455\u20133465 (2010).","journal-title":"J. Clin. Invest."},{"key":"56151_CR56","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1128\/IAI.67.8.4231-4236.1999","volume":"67","author":"CY Chiang","year":"1999","unstructured":"Chiang, C. Y., Kyritsis, G., Graves, D. T. & Amar, S. Interleukin-1 and tumor necrosis factor activities partially account for calvarial bone resorption induced by local injection of lipopolysaccharide. Infect. Immun. 67, 4231\u20134236 (1999).","journal-title":"Infect. Immun."},{"key":"56151_CR57","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1101\/gad.1119303","volume":"17","author":"S Kim","year":"2003","unstructured":"Kim, S. et al. Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation. Genes Dev. 17, 1979\u20131991 (2003).","journal-title":"Genes Dev."},{"key":"56151_CR58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/ki.2008.242","volume":"74","author":"A Yajima","year":"2008","unstructured":"Yajima, A., Inaba, M., Tominaga, Y. & Ito, A. Bone formation by minimodeling is more active than remodeling after parathyroidectomy. Kidney Int. 74, 775\u2013781 (2008).","journal-title":"Kidney Int."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56151-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56151-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:59:19Z","timestamp":1671281959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56151-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,27]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["56151"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-56151-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,27]]},"assertion":[{"value":"28 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19895"}}